4//SEC Filing
Duchemin Jeffrey 4
Accession 0001209191-19-024470
CIK 0001123494other
Filed
Apr 11, 8:00 PM ET
Accepted
Apr 12, 4:06 PM ET
Size
10.7 KB
Accession
0001209191-19-024470
Insider Transaction Report
Form 4
Duchemin Jeffrey
Chief Executive Officer
Transactions
- Sale
Common Stock
2019-04-11$4.51/sh−12,425$56,037→ 831,288 total - Sale
Common Stock
2019-04-12$4.65/sh−400$1,860→ 830,888 total - Sale
Common Stock
2019-04-10$4.50/sh−6,332$28,494→ 843,713 total
Footnotes (7)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $4.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).
- [F3]Includes (a) a deferred stock award of 56,517 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on March 7, 2020, 2021 and 2022, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 113,034 restricted stock units which shall vest in four equal installments on January 1, 2020, 2021, 2022 and 2023; (c) a deferred stock award of 70,833 restricted stock units which vest in equal installments on January 1, 2020, 2021 and 2022; (d) a deferred stock award of 178,804 restricted stock units which shall vest in equal installments on January 1, 2020 and 2021; (e) a deferred stock award of 72,916 restricted stock units which shall vest on January 1, 2020;
- [F4]continuation of footnote 3 above: (f) a deferred stock award of 94,444 restricted stock units with performance based vesting conditions, which if earned shall vest in equal installments on May 24, 2019, 2020 and 2021, and are contingent upon achievement of a performance condition tied to relative shareholder return; and (g) 257,165 shares of common stock held by the Reporting Person.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $4.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5).
- [F6]Includes the awards referenced in clauses (a) through (f) of footnotes (3) and (4) above, plus 244,740 shares of common stock held by the Reporting Person.
- [F7]Includes the awards referenced in clauses (a) through (f) of footnotes (3) and (4) above, plus 244,340 shares of common stock held by the Reporting Person.
Documents
Issuer
HARVARD BIOSCIENCE INC
CIK 0001123494
Entity typeother
Related Parties
1- filerCIK 0001585223
Filing Metadata
- Form type
- 4
- Filed
- Apr 11, 8:00 PM ET
- Accepted
- Apr 12, 4:06 PM ET
- Size
- 10.7 KB